<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50302">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01938729</url>
  </required_header>
  <id_info>
    <org_study_id>13-148</org_study_id>
    <nct_id>NCT01938729</nct_id>
  </id_info>
  <brief_title>Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma</brief_title>
  <official_title>Phase I Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan-Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan-Kettering Cancer Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I study, which means we want to find out what effects, good and/or bad, this
      combination of drugs may have on the patient and the liver cancer at different dose levels.
      On this study, both drugs given have been used in other patients for treatment of
      cholangiocarcinoma and other gastrointestinal cancers. Both drugs are approved by the food
      and drug administration (FDA) for treatment of liver cancer, but the two drugs have only
      been combined in a few patients.

      That means that in this trial we also want to find out if this combination is safe.

      The study will also evaluate if this treatment works in delaying or stopping the cancer from
      coming back after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and Toxicity</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>All toxicities will be rated as per the NCI Common Toxicity Criteria (CTC AE version 4.0) except neurosensory and hepatic enzyme toxicities related to intrahepatic pump therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence Free Survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>we will evaluate the recurrence-free survival of patients in this trial using Kaplan-Meier methods.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <condition>Peripheral Cholangiocarcinoma</condition>
  <condition>Cholangiolar Carcinoma</condition>
  <condition>Cholangiocellular Carcinoma) (ICC)</condition>
  <arm_group>
    <arm_group_label>HAI with FLOXURIDINE &amp; DEXAMETHASONE  &amp;  GEMCITABINE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open-label single arm study. The patients will start therapy 4 weeks postoperatively. They will receive HAI FUDR/Dex and systemic gemcitabine in the following dose escalation levels of gemcitabine. The dose of HAI FUDR will be fixed. A classic 3+3 cohort dose escalation scheme will be used to identify the MTD of the combination.
Level 1: Systemic gemcitabine 650mg/m2 Day 1 and 15 and HAI FUDR/Dex 0.12mg/kg/day Day 1-14 Level 2.Systemic gemcitabine 800mg/m2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14 Level 3. Systemic gemcitabine 1000mg/m2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver resection and placement of hepatic artery infusion pump</intervention_name>
    <arm_group_label>HAI with FLOXURIDINE &amp; DEXAMETHASONE  &amp;  GEMCITABINE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLOXURIDINE</intervention_name>
    <arm_group_label>HAI with FLOXURIDINE &amp; DEXAMETHASONE  &amp;  GEMCITABINE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DEXAMETHASONE</intervention_name>
    <arm_group_label>HAI with FLOXURIDINE &amp; DEXAMETHASONE  &amp;  GEMCITABINE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GEMCITABINE</intervention_name>
    <arm_group_label>HAI with FLOXURIDINE &amp; DEXAMETHASONE  &amp;  GEMCITABINE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed intrahepatic cholangiocarcinoma (also variously reported as
             peripheral cholangiocarcinoma, cholangiolar carcinoma or cholangiocellular carcinoma)
             (ICC). Confirmation of the diagnosis must be made at MSKCC (outside slides will be
             reviewed by MSKCC pathologists).

          -  Patients must have had a complete resection and hepatic artery pump placement

          -  KPS ≥ 80%

          -  Preoperative laboratory values within 14 days of registration must be:

          -  Serum albumin must be &gt;2.5 g/dl

          -  WBC must be &gt;3500 cells/mm3

          -  Platelet count must be &gt;100,000/mm3

          -  International normalized ratio (INR) must be less than 1.5 in patients not on
             Coumadin therapy

          -  Preoperative laboratory values within 14 days of registration must be:

          -  Bilirubin ≤ 1.5 mg/dl

          -  Age &gt;18 years

          -  Patients must be able to understand and sign informed consent

          -  Prior chemotherapy is allowed

        Exclusion Criteria:

          -  Prior treatment with HAI chemotherapy

          -  Extrahepatic metastases including nodal disease

          -  Prior external beam radiation therapy to the liver

          -  Diagnosis of sclerosing cholangitis

          -  Diagnosis of Gilbert's disease

          -  Patients that have concurrent malignancies (except localized basal cell or squamous
             cell skin cancers)

          -  Female patients who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Cercek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Cercek, MD</last_name>
    <phone>646-888-4189</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael D'Angelica, MD</last_name>
    <phone>212-639-3226</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center at Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
    <contact_backup>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact_backup>
    <investigator>
      <last_name>Andrea Cercek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center at Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andera Cercek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
    <contact_backup>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact_backup>
    <investigator>
      <last_name>Andrea Cercek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center Sleepy Hollow</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>September 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HEPATIC ARTERIAL INFUSION</keyword>
  <keyword>FLOXURIDINE</keyword>
  <keyword>DEXAMETHASONE</keyword>
  <keyword>GEMCITABINE</keyword>
  <keyword>Pump</keyword>
  <keyword>13-148</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
